前收市價 | 0.6000 |
開市 | 0.6000 |
買盤 | 0.0500 |
賣出價 | 0.3000 |
拍板 | 17.50 |
到期日 | 2024-05-17 |
今日波幅 | 0.6000 - 0.6000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 77 |
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.